NEWS・COLUMN
We send the latest information from SMC Laboratories.
Announcement of Poster Presentation Japan Respiratory Society, Kanto Branch Meeting (No. 267) November 22, 2025
SMC Laboratories will present a poster at the 267th Kanto Branch Meeting of the Japan Respiratory Society, to …
Made-to-Order Service Example: Optimization of an ANIT-Induced Chronic Cholestasis Model for Drug Efficacy Evaluation
SMC Laboratories’ Made-to-Order (MTO) service is designed to meet research needs that are difficult to reprodu…
Made-to-Order Service Example: Development of a Polycystic Kidney Disease Model Using DBA/2FG-pcy Mice
The DBA/2FG-pcy mouse is an autosomal recessive model of polycystic kidney disease that spontaneously develops…
SMC Laboratories to Participate in BIO-Europe 2025 (Austria) Online
SMC Laboratories will be participating digitally in BIO-Europe 2025, one of the largest bio-health conventions…
Made to Order Case Study: Establishment of Cecal Cannulation Dosing in a Colitis Model
SMC Laboratories’ MTO (Made to Order) service is designed to address research needs that cannot be met by exis…
Made to Order Case Example: Establishment of a Unilateral Ureteral Obstruction (UUO) Model in Guinea Pigs
SMC Laboratories’ MTO (Made to Order) service is designed to address evaluation needs that cannot be met with …
Poster Presentation at APASL STC 2025 Tokyo
We are pleased to announce that we presented a poster at APASL STC 2025 Tokyo, under Poster ID PF1-5 10244. Ti…
Announcement of Participation in BioJapan 2025 Partnering
We are pleased to announce our participation in BioJapan 2025, which will be held from October 8th to 10th at …
Pulmonary Function Assessment in the Elastase-Induced Emphysema Model
At our company, we conduct preclinical evaluations using the elastase-induced emphysema (PPE: porcine pancreat…
A New Positive Control Option in the UUO Model: Dapagliflozin
We have confirmed the renoprotective effect of the SGLT2 inhibitor dapagliflozin (20 mg/kg, oral administratio…
Publication Announcement: Study Using Our IPF Model
A research article utilizing our bleomycin-induced pulmonary fibrosis (IPF) mouse model has been published in …
A New Phase in MASH Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist)
In 2024, the U.S. FDA approved Resmetirom (a THR-β agonist) as the first therapeutic agent for MASH. In August…